Ubs Group Ag Werewolf Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 15,479 shares of HOWL stock, worth $27,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,479

Previous 9,808 57.82%

Holding current value

$27,397

Previous $23,000 39.13%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.71 - $2.95 $9,697 - $16,729	5,671 Added 57.82%	15,479 $32,000
Q2 2024 Aug 13, 2024	BUY	$2.34 - $6.75 $22,864 - $65,954	9,771 Added 26408.11%	9,808 $23,000
Q1 2024 May 13, 2024	SELL	$3.92 - $7.91 $3,774 - $7,617	-963 Reduced 96.3%	37 $0
Q1 2023 May 12, 2023	SELL	$1.98 - $4.3 $887 - $1,926	-448 Reduced 30.94%	1,000 $2,000
Q4 2022 Feb 08, 2023	SELL	$1.53 - $4.73 $1,533 - $4,739	-1,002 Reduced 40.9%	1,448 $2,000
Q3 2022 Nov 10, 2022	SELL	$4.14 - $7.42 $7,480 - $13,407	-1,807 Reduced 42.45%	2,450 $11,000
Q2 2022 Aug 10, 2022	BUY	$3.43 - $5.98 $7,388 - $12,880	2,154 Added 102.43%	4,257 $18,000
Q1 2022 May 16, 2022	SELL	$3.71 - $12.22 $27,290 - $89,890	-7,356 Reduced 77.77%	2,103 $9,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.65 $89,773 - $138,023	7,820 Added 477.12%	9,459 $113,000
Q3 2021 Nov 15, 2021	BUY	$13.89 - $20.31 $8,875 - $12,978	639 Added 63.9%	1,639 $28,000
Q2 2021 Aug 13, 2021	BUY	$11.6 - $17.44 $11,600 - $17,440	1,000 New	1,000 $17,000

Others Institutions Holding HOWL

# of Institutions

Shares Held

31.8M

Call Options Held

700

Put Options Held

500

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $52.3M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account